Key Takeaways For Treating Patients Diagnosed With Cholangiocarcinoma

EP: 1.Intrahepatic Cholangiocarcinoma Overview

EP: 2.Risk Factors Leading to Various Liver Cancers

EP: 3.Clinical Presentations of Patients With Cholangiocarcinoma

EP: 4.The Role of Biomarker Testing in Diagnosing Cholangiocarcinoma

EP: 5.First- and Second-Line Treatment Options for Intrahepatic Cholangiocarcinoma With FGFR2 Fusions or Alterations

EP: 6.Next-Gen Inhibitors Shaping Cholangiocarcinoma Treatment Landscape

EP: 7.Key Highlights For Patient Education Surrounding FGFR Inhibitors

EP: 8.Common Adverse Events Associated With FGFRi Therapy

EP: 9.Patient Perspective Regarding FGFRi Adverse Event Profiles

EP: 10.Symptoms Associated With Eye-Related Toxicities Amid FGFRi Therapy

EP: 11.Monitoring and Managing Hyperphosphatemia

EP: 12.Navigating FGFRi Therapy Adverse Effects: Nail Toxicities

EP: 13.FGFRi-Related Stomatitis and Dry Mouth Impacting Patient Quality of Life

Now Viewing

EP: 14.Key Takeaways For Treating Patients Diagnosed With Cholangiocarcinoma

This page is funded by Taiho Oncology, Inc. The faculty and publisher are solely responsible for this content. Taiho does not recommend or endorse the use of its products other than as described in the approved labeling. The content of this page is not medical advice and does not replace independent medical judgment.

This is a video synopsis/summary of an OncLive Insights involving Lipika Goyal, MD; Chaundra Bishop; R. Katie Kelley, MD; and Caroline Kuhlman, NP.

FGFR inhibitors such as pemigatinib and futibatinib can cause several adverse effects, including hyperphosphatemia, nail toxicities, stomatitis, and dry mouth. It is critical that patients report all adverse effects fully to their care team for optimal management. Early intervention can often control symptoms without needing treatment discontinuation. Practitioners should set expectations up front for frequent adverse effects such as nail changes, which will happen to virtually all patients to some degree. However, most adverse effects, although bothersome, are not dangerous or severe enough to require hospitalizations. The efficacy of FGFR inhibitors makes it worthwhile to perseverate through short-term quality of life impacts. Proactive strategies for adverse effect prevention and treatment allow most patients to remain on therapy long term. Ultimately, the goal is maximizing time on treatment to achieve prolonged disease control.

Video synopsis is AI-generated and reviewed by OncLive® editorial staff.